Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Benda Adds to Ownership of Cancer Gene Therapy Drug

publication date: Jun 20, 2007
Benda Now Holds 60% of SiBiono Benda Pharma (Bulletin Board: BPMA) incrementally increased its ownership of Gendicine, the first gene therapy for cancer, by buying another 2.56% of the stock in the maker of Gendicine, SiBiono. With this latest purchase, Benda now owns 60.13% of the total number of outstanding SiBiono shares. Although Benda produces many traditional Chinese medications, Gendicine is a western style drug for cancer that has been on the market since 2004. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here